Jordan S. Fridman
Incyte (United States)(US)
Publications by Year
Research Areas
Cytokine Signaling Pathways and Interactions, Myeloproliferative Neoplasms: Diagnosis and Treatment, HER2/EGFR in Cancer Research, Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments
Most-Cited Works
- → Control of apoptosis by p53(2003)1,397 cited
- → Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis(2010)1,159 cited
- → A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy(2002)1,034 cited
- → Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy(2004)947 cited
- → Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms(2010)818 cited
- → Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity(2010)552 cited
- → Dissecting p53 tumor suppressor functions in vivo(2002)484 cited
- → Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050(2010)458 cited
- → Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer(2006)375 cited
- → An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo(2003)349 cited